DUBLIN – Jecure Therapeutics Inc. raised $20 million in series A funding for the discovery and development of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis, based on new insights into the sterile inflammatory processes that drive the disease.